Adebrelimab, CAS 2247114-85-6

Product Description: Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC)[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Zhiwei Liu, et al. The Synergistic Effects of Pyrotinib and SHR-1316 on HER2-positve breast cancer. Research Square. May 19th, 2022./[2]Wanpu Yan, et al. Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial. J Thorac Oncol. 2022 Sep 30;S1556-0864(22)01822-6.

CAS Number: 2247114-85-6

Molecular Weight: N/A

Compound Purity: 97.84

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Apoptosis;PD-1/PD-L1

• Artikelnummer: MEXHY-P99422-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99422-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK